secwatch.observer — SEC 8-K summary
======================================

Issuer:     Organogenesis Holdings Inc. (ORGO)
CIK:        0001661181
Form:       8-K
Filed at:   2025-09-25T23:59:59+00:00
Accession:  0001193125-25-217810
Event type: other_material
Sentiment:  negative
Materiality: 0.80
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Organogenesis second Phase 3 ReNu knee OA trial misses primary endpoint; pre-BLA meeting planned
--------------------------------------------------------------------------------

- Second Phase 3 (n=594) did not meet primary endpoint: WOMAC pain reduction difference -0.5 favoring ReNu (p=0.0393 vs target p=0.023).
- ReNu showed numerical improvement in baseline pain reduction vs first Phase 3 (-6.9 vs -6.0); safety profile favorable.
- Statistically significant maintenance of function (p<0.0001) reported in second study.
- Company to request pre-BLA meeting with FDA by end of October 2025 to discuss combined efficacy from both Phase 3 trials.
- First Phase 3 met primary endpoint (difference -0.7, p=0.0177); ReNu has FDA RMAT designation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1661181/000119312525217810/0001193125-25-217810-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1661181/000119312525217810/d870311d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-217810

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer